A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

Inclusion Criteria: * Participants with type 2 diabetes (T2D) at least 6 months before screening * Participants treated for T2D with diet and exercise, with or without metformin * Have a glycated hemoglobin A1c (HbA1c) value of ≥ 7.5% and ≤10.5% * Have had a stable body weight for 3 months and body mass index (BMI) of 27.0 to 45.0 kilograms per meter squared (kg/m²) * Male participants who agree to use effective methods of contraception and female participants not of childbearing potential Exclusion Criteria: * Have a history of or current cardiovascular, respiratory, hepatic, renal, GI, endocrine (apart from T2D), hematological, or neurological disorders capable of altering the absorption, metabolism, or elimination of drugs * Have type 1 diabetes mellitus or latent autoimmune diabetes in adults or maturity-onset diabetes of the young * Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or severe non-proliferative diabetic retinopathy * Have known allergies to GLP-1 receptor agonists